NZ511720A - Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis - Google Patents
Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasisInfo
- Publication number
- NZ511720A NZ511720A NZ511720A NZ51172099A NZ511720A NZ 511720 A NZ511720 A NZ 511720A NZ 511720 A NZ511720 A NZ 511720A NZ 51172099 A NZ51172099 A NZ 51172099A NZ 511720 A NZ511720 A NZ 511720A
- Authority
- NZ
- New Zealand
- Prior art keywords
- ester
- treatment
- halogen
- sulphate
- independently
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Use of a compound of formula (I) for the preparation of a medicament for the treatment or prevention of a Trypanosoma or Plasmodium infection, wherein: Q1 is -C(R1)2- or -C(O)-, Q2 is -C(R1)2-, -C(R1)(Y)-, -C(Y)- or -CH2-CH2-, Q3 and Q6 independently are -H or -C(R1)3, Q4 is -C(R1)2-, -C(O)-, hydroxyvinylidine or methyl methylene, Q5 is -C(R1)2- or -C(O)-, X and Y independently is -H, halogen, -OH, C1-6alkoxy, or C1-6alkyl, R2 is -H, -OH, halogen, C1-6alkyl, C1-6alkoxy, -OR3, an ester, a thioester, a thioacetal, a sulphate ester, a sulphonate ester, or a carbamate or R2, together with the R1 that is bonded to the same carbon atom is =O, R3 is -S(O)(O)-OM, S(O)(O)-O-CH2-CH(O-C(O)-R6)-CH2-O-C(O)-R6, P(O)(O) O CH2 CH(O C(O)-R7)-CH2-O-C(O)-R7, a glucuronide group of structure (A), or R3 is C1-18alkyl, C2 18alkenyl, C2-18alkynyl, a C1-18ester or a C1-18thioester, wherein any of the C1-18 or C2-18 moieties are optionally substituted by -ORPR, -NHRPR, or -SRPR, or R3 is a C1-18fatty acid, C2-10alkynyl, (J)n-phenyl-C1-5alkyl, (J)n-phenyl-C2-5alkenyl, R5 and R6 are independently, straight or branched C1-14alkyl, R7 is C1-14 straight or branched chain alkyl or a gucuronide group of structure (A), RPR is -H or a protecting group, n is 0, 1, 2 or 3, J is halogen, C1-4alkyl, C2-4alkenyl, C1-4alkoxy, carboxy, nitro, sulphate, sulphonyl, C1 6carboxyl ester or C1-6sulphate ester, M is hydrogen, sodium, -S(O)(O)-O-CH2-CH(O-C(O)-R6)-CH2-O-C(O)-R6, P(O)(O) O CH2 CH(O-C(O)-R7)-CH2-O-C(O)-R7 or a glucuronide group of structure (A), The dotted lines represent an optional double bond, Provided that the compound is not dehydroepiandrosterone, or the 3â-sulphate thereof.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10992398P | 1998-11-24 | 1998-11-24 | |
| US12408799P | 1999-03-11 | 1999-03-11 | |
| US12605699P | 1999-03-23 | 1999-03-23 | |
| PCT/US1999/028079 WO2000032201A2 (en) | 1998-11-24 | 1999-11-24 | Use of 17-ketosteroids for the treatment of malaria and trypanosomiasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ511720A true NZ511720A (en) | 2002-12-20 |
Family
ID=27380739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ511720A NZ511720A (en) | 1998-11-24 | 1999-11-24 | Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1135138A2 (en) |
| JP (1) | JP2002531407A (en) |
| KR (2) | KR20070004149A (en) |
| CN (1) | CN1348373A (en) |
| AP (1) | AP1584A (en) |
| AU (2) | AU776853B2 (en) |
| BR (1) | BR9915623A (en) |
| CA (1) | CA2356539A1 (en) |
| HK (1) | HK1043319A1 (en) |
| IL (1) | IL142941A0 (en) |
| NZ (1) | NZ511720A (en) |
| OA (1) | OA11715A (en) |
| WO (1) | WO2000032201A2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US20070129282A1 (en) | 1998-11-24 | 2007-06-07 | Ahlem Clarence N | Pharmaceutical treatments and compositions |
| CA2375647A1 (en) | 1999-07-08 | 2001-01-18 | Patrick T. Prendergast | Use of flavones, coumarins and related compounds to treat infections |
| CA2670236C (en) | 1999-09-30 | 2012-06-05 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment of androgen receptor driven conditions |
| US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
| US7910755B2 (en) | 2004-09-29 | 2011-03-22 | Harbor Biosciences, Inc. | Stem cell expansion and uses |
| US8217025B2 (en) | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
| KR100786126B1 (en) * | 2007-08-14 | 2007-12-18 | 주식회사 아바코 | Scribe method of cutting object by sustenance contactless flatness and scribe head apparatus of cutting object by sustenance contactless flatness |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL194728C (en) * | 1987-04-16 | 2003-01-07 | Hollis Eden Pharmaceuticals | Pharmaceutical preparation suitable for the prophylaxis or therapy of a retroviral infection or a complication or consequence thereof. |
| WO1997038695A1 (en) * | 1996-04-17 | 1997-10-23 | Prendergast Patrick T | Dhea combination therapy |
| WO1998047516A1 (en) * | 1997-04-17 | 1998-10-29 | Prendergast Patrick T | Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors |
-
1999
- 1999-11-24 JP JP2000584896A patent/JP2002531407A/en active Pending
- 1999-11-24 IL IL14294199A patent/IL142941A0/en unknown
- 1999-11-24 BR BR9915623-7A patent/BR9915623A/en not_active Application Discontinuation
- 1999-11-24 EP EP99960591A patent/EP1135138A2/en not_active Withdrawn
- 1999-11-24 WO PCT/US1999/028079 patent/WO2000032201A2/en not_active Application Discontinuation
- 1999-11-24 NZ NZ511720A patent/NZ511720A/en unknown
- 1999-11-24 OA OA1200100127A patent/OA11715A/en unknown
- 1999-11-24 KR KR1020067026568A patent/KR20070004149A/en not_active Application Discontinuation
- 1999-11-24 CN CN99813696A patent/CN1348373A/en active Pending
- 1999-11-24 AU AU17453/00A patent/AU776853B2/en not_active Ceased
- 1999-11-24 AP APAP/P/2001/002182A patent/AP1584A/en active
- 1999-11-24 KR KR1020017006523A patent/KR20010101073A/en not_active Application Discontinuation
- 1999-11-24 CA CA002356539A patent/CA2356539A1/en not_active Abandoned
-
2002
- 2002-07-12 HK HK02105184.3A patent/HK1043319A1/en unknown
-
2004
- 2004-12-08 AU AU2004237812A patent/AU2004237812B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1135138A2 (en) | 2001-09-26 |
| CN1348373A (en) | 2002-05-08 |
| KR20070004149A (en) | 2007-01-05 |
| WO2000032201A2 (en) | 2000-06-08 |
| CA2356539A1 (en) | 2000-06-08 |
| AU2004237812B2 (en) | 2007-11-29 |
| OA11715A (en) | 2005-03-14 |
| AP1584A (en) | 2006-03-01 |
| KR20010101073A (en) | 2001-11-14 |
| AU2004237812A1 (en) | 2005-01-13 |
| AU1745300A (en) | 2000-06-19 |
| JP2002531407A (en) | 2002-09-24 |
| AP2001002182A0 (en) | 2001-06-30 |
| IL142941A0 (en) | 2002-04-21 |
| WO2000032201A3 (en) | 2000-12-21 |
| BR9915623A (en) | 2001-08-14 |
| HK1043319A1 (en) | 2002-09-13 |
| AU776853B2 (en) | 2004-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ511720A (en) | Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis | |
| AU1039688A (en) | 3(2h)pyridazinone, process for its preparation and antagonistic agent against srs-a containing it | |
| BR9810657A (en) | "process of preparing a substituted perhydroisoindole" | |
| NO995590D0 (en) | 20-Aryl-5 <alpha> -pregnan derivatives | |
| SG76479A1 (en) | Pleuromutilin derivatives | |
| FI91070B (en) | Improvement in the synthesis of 6-methylene derivatives of androsta-1,4-diene-3,17-dione | |
| NO995935L (en) | 17 <beta> -alloxy (thio) alkyl-androstane derivatives for modulating meiosis | |
| TR199901089T2 (en) | Aminehydrofluorides and their use as oral hygiene preparations. | |
| MY131544A (en) | Fluorinated 4-aminoandrostadienone derivatives and process for their preparation | |
| DE69029781D1 (en) | Anthracycline glycoside derivatives and process for their preparation | |
| DE3569729D1 (en) | 3-aminoazetidine, its salts, process for their preparation and intermediates | |
| HU9202100D0 (en) | New 16-methyl-pregna-1,4-diene-3,20-dione derivatives | |
| NO931716L (en) | PROCEDURE FOR THE PREPARATION OF N, N-DIALKYLGYLAMAMINE COMPOUNDS | |
| GR3032845T3 (en) | Indole derivatives as 5-alpha-reductase-1-inhibitors | |
| PT94906A (en) | (23-VINCRISTINOYLICOS) AND N- (5'-NORANIDRO-23-VINBLASTINOYLICOS) DERIVATIVES OF 1-AMINO-METHYL-PHOSPHONIC ACID | |
| TW254937B (en) | Benzocycloheptene derivative and process for preparation thereof | |
| DK1137660T3 (en) | 22S-hydroxycholesta-8,14-diene derivatives with meios regulating activity | |
| DE69531507D1 (en) | INTERMEDIATE PRODUCTS FOR PRODUCING A PHARMACEUTICALLY ACTIVE CONNECTION | |
| MY102002A (en) | Phenethylamine derivatives | |
| GT199300022A (en) | STEROID GLYCOSIDES SYNTHESIS PROCEDURES | |
| MY105475A (en) | Steroid compounds. | |
| MX170821B (en) | PROCEDURE FOR THE PREPARATION OF 3- [2- [4- (4-FLUOROBENZOIL) -1-PIPERIDINYL] ETHYL] -2,4- (1H, 3H) -QUINAZOLINDIONA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |